Clincosm LogoSign in Get a demo

kras p.g12c

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

KRAS P.G12C, Pancreatic Cancer Trial in Beijing (JAB-21822)

Not yet recruiting
  • KRAS P.G12C
  • Pancreatic Cancer
  • Beijing, Beijing, China
  • +1 more
Aug 18, 2023

KRAS P.G12C Trial in Worldwide (D3S-001)

Recruiting
  • KRAS P.G12C
  • Detroit, Michigan
  • +12 more
Jan 16, 2023

NSCLC Stage IV, KRAS P.G12C Trial in Worldwide (Adagrasib)

Not yet recruiting
  • NSCLC Stage IV
  • KRAS P.G12C
  • Brussels, Belgium
  • +26 more
Jan 3, 2023

KRAS P.G12C, Non Small Cell Lung Cancer Trial in France (Sotorasib 120Mg Tab)

Recruiting
  • KRAS P.G12C
  • Non Small Cell Lung Cancer
  • Sotorasib 120Mg Tab
  • Lyon, France
  • +3 more
Dec 16, 2022

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Recruiting
  • Nsclc
  • KRAS P.G12C
    • Paris, France
    • +2 more
    Aug 9, 2022

    NSCLC Stage III, KRAS P.G12C Trial in Spain (Sotorasib)

    Recruiting
    • Non-small Cell Lung Cancer Stage III
    • KRAS P.G12C
    • Badalona, Barcelona, Spain
    • +19 more
    Jul 6, 2022

    KRAS P.G12C, NSCLC, Colorectal Cancer Trial in China (JAB-21822, JAB-3312)

    Recruiting
    • KRAS P.G12C
    • +3 more
    • Beijing, Beijing, China
    • +23 more
    Jun 29, 2022

    Studying Pathways of Resistance in KRAS-driven Cancers

    Not yet recruiting
    • KRAS P.G12C
    • FoundationOne® Liquid CDx
    • (no location specified)
    Mar 9, 2022

    Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer Trial (Sotorasib, Liposomal Irinotecan

    Not yet recruiting
    • Pancreatic Cancer
    • +3 more
    • (no location specified)
    Feb 11, 2022